Rating Agencies

Share recommendations

Made with ❤ von BGFL

#BGFLapp * beta

Valuable background information and well-founded assessments of individual stocks are provided by the studies of the research houses. On this page, Boersengefluester.de (BGFL) provides an integrated overview of all analyst recommendations that come in via the EQS Group newsfeed - enriched with current stock charts as well as meaningful key figure tables and investor information from BGFL. Tip: You are also welcome to use the EQS newsfeed, which we have also enhanced with all the latest company news from our coverage universe.

Last 24H

Today

Yesterday

7 days

All

All Issuers BankM AG GBC AG Montega AG

25.10.2023 10:02AM

Study issued by GBC AG

Vectron Systems AG (von GBC AG): BUY

BUY

9 months 2023: Significant increase in sales and earnings achieved; 2023 forecasts raised and target price increased slightly; BUY According to preliminary figures, Vectron Systems AG (short: Vectron) achieved a significant growth in turnover and result in the third quarter, which seamlessly continues the positive development of the previo [ … ]

Original Research

DE000A0KEXC7 A0KEXC

Vectron Systems

23.10.2023 10:11AM

Study issued by First Berlin Equity Research GmbH

ad pepper media International N.V. (von First Berlin Equity Research GmbH): Buy

Buy

First Berlin Equity Research hat ein Research Update zu ad pepper media International N.V. (ISIN: NL0000238145) veröffentlicht. Analyst Dr. Karsten von Blumenthal bestätigt seine BUY-Empfehlung und senkt das Kursziel von EUR 3,50 auf EUR 3,00. Zusammenfassung: ad pepper media (APM) hat vorläufige Zahlen für das dritte Quarta [ … ]

Original Research

NL0000238145 940883

ad pepper media

18.10.2023 02:51PM

Study issued by First Berlin Equity Research GmbH

MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen

Kaufen

First Berlin Equity Research hat ein Research Update zu MPH Health Care AG (ISIN: DE000A289V03) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung und erhöht das Kursziel von EUR 59,00 auf EUR 62,00. Zusammenfassung: Der Sechsmonatsbericht spiegelt die Kursentwicklung der beiden wichtigsten börsennotierten B [ … ]

Original Research

DE000A289V03 A289V0

MPH Health Care

31.03.2022 11:02AM

Study issued by GBC AG

Bitcoin Group SE (von GBC AG): BUY

BUY

Preliminary business figures 2021 - Very good development with results above our forecasts On March 29, 2022, Bitcoin Group SE published the preliminary business figures for the year 2021. Accordingly, sales increased by 56.6% to EUR23.5 million (previous year: EUR15.0 million). EBITDA increased by 85.7% to EUR19.5 million (previous year: EUR10. [ … ]

Original Research

DE000A1TNV91 A1TNV9

Bitcoin Group

19.01.2022 09:32AM

Study issued by GBC AG

The NAGA Group AG (von GBC AG): BUY

BUY

Strong revenue and earnings growth in 2021; guidance for 2022 significantly above our expectations; estimates and share price target raised According to preliminary figures for the past financial year 2021, The NAGA Group AG (short to: NAGA) achieved significant revenue growth as expected. Compared to the previous year, consolidated sales more t [ … ]

Original Research

DE000A161NR7 A161NR

Naga Group

11.01.2022 01:01PM

Study issued by BankM AG

All for One Group SE (von BankM AG): Kaufen

Kaufen

2021/22 receives boost from acquisitions and CONVERSION/4 Following the successful conclusion of the 2020/21 fiscal year, the focus of All for One Group SE (ISIN DE0005110001, Prime Standard, A1OS GY) is now on 2021/22: the three recently completed acquisitions will provide an inorganic boost to growth but will also promote organic growth. The a [ … ]

Original Research

DE0005110001 511000

All for One Group

10.12.2021 12:31PM

Study issued by GBC AG

HAEMATO AG (von GBC AG): Management Interview

Management Interview

In operational terms, HAEMATO AG is heading for a record year following the acquisition of M1 Aesthetics GmbH. In addition, the expansion of their private label business is increasingly coming into focus. In this regard, the company plans to expand its portfolio with a botulinum toxin product under its own brand. GBC analyst Cosmin Filker spoke wi [ … ]

Original Research

DE000A289VV1 A289VV

Haemato

« Previous
Next »

Showing 351 to 357 of 357 results

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.

Rating Agencies